Prolixin Decanoate, Modecate Decanoate 
Moditen Enanthate , Prolixin Enanthate
Moditen HCl , Permitil, Prolixin
Classifications: central nervous system agent; psychotherapeutic; antipsychotic; phenothiazine
Prototype: Chlorpromazine
Pregnancy Category: C


1 mg, 2.5 mg, 5 mg, 10 mg tablets; 2.5 mg/5 mL elixir; 5 mg/mL oral concentrate; 2.5 mg/mL, 25 mg/mL injection


Potent phenothiazine, antipsychotic agent. Blocks postsynaptic dopamine receptors in the brain. Similar to other phenothiazines with the following exceptions: more potent per weight, higher incidence of extrapyramidal complications, and lower frequency of sedative, hypotensive, and antiemetic effects.

Therapeutic Effects

Effective for treatment of antipsychotic symptoms including schizophrenia.


Management of manifestations of psychotic disorders.

Unlabeled Uses

As antineuralgia adjunct.


Known hypersensitivity to phenothiazines; subcortical brain damage, comatose or severely depressed states, blood dyscrasias, renal or hepatic disease. Safety during pregnancy (category C) or lactation is not established. Parenteral form not recommended for children <12 y.

Cautious Use

With anticholinergic agents, other CNS depressants; older adults, previously diagnosed breast cancer; cardiovascular diseases; pheochromocytoma; history of convulsive disorders; patients exposed to extreme heat or phosphorous insecticides; peptic ulcer; respiratory impairment.

Route & Dosage

Adult: PO 0.5–10 mg/d in 1–4 divided doses (max: of 20 mg/d) IM/SC HCl 2.5–10 mg/d divided q6–8h (max: 10 mg/d); Decanoate 12.5–25 mg q1–4wk; Enanthate 25 mg q2wk

Dementia Behavior
Geriatric: PO 1–2.5 mg/d, may increase every 4–7 d by 1–2.5 mg/d (max: 20 mg/d in 2–3 divided doses)



Adverse Effects (1%)

CNS: Extrapyramidal symptoms (resembling Parkinson's disease), tardive dyskinesia, sedation, drowsiness, dizziness, headache, mental depression, catatonic-like state, impaired thermoregulation, grand mal seizures. CV: Tachycardia, hypertension, hypotension. GI: Dry mouth, nausea, epigastric pain, constipation, fecal impaction, cholecystic jaundice. Urogenital: Urinary retention, polyuria, inhibition of ejaculation. Hematologic: Transient leukopenia, agranulocytosis. Skin: Contact dermatitis. Body as a Whole: Peripheral edema. Special Senses: Nasal congestion, blurred vision, increased intraocular pressure, photosensitivity. Endocrine: Hyperprolactinemia.


Drug: Alcohol and other cns depressants may potentiate depressive effects; decreases seizure threshold, may need to adjust dosage of anticonvulsants. Herbal: Kava-kava may increase risk and severity of dystonic reactions.


Absorption: HCl is readily absorbed PO and IM; decanoate, enanthate have delayed IM absorption. Onset: 1 h HCl; 24–72 h decanoate, enanthate. Peak: 0.5 h PO; 1.5–2 h IM HCl. Duration: 6–8 h HCl; 1–6 wk decanoate; 2–4 wk enanthate. Distribution: Crosses blood–brain barrier and placenta. Metabolism: Metabolized in liver. Half-Life: 15 h HCl; 3.6 d enanthate; 7–10 d decanoate.

Nursing Implications

Assessment & Drug Effects

Patient & Family Education

Common adverse effects in italic, life-threatening effects underlined; generic names in bold; classifications in SMALL CAPS; Canadian drug name; Prototype drug